Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker’s stock rose 1.7% in premarket trading after it ...

Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...